成人肌炎患者抗FHL1自身抗体的纵向随访分析
该研究采用ELISA检测449例特发性炎症性肌病(IIM)患者诊断时血清抗FHL1自身抗体,并与自身免疫病对照、神经肌肉疾病对照和健康对照比较,发现IIM中抗FHL1阳性率为27%,且抗FHL1水平与基线CK、MYOACT疾病活动度相关,与MMT-8呈负相关,部分患者随访中转阴。
要点
- IIM患者抗FHL1阳性率为27%(122/449),高于自身免疫病和神经肌肉疾病对照的9%(13/146)及健康对照的3%(3/100),P均<0.001。
- 抗FHL1阳性IIM患者诊断年龄较阴性组更年轻(P=0.05),25%的其他自身抗体为阴性。
- 基线抗FHL1水平与CK(r=0.62,P=0.01)、MYOACT疾病活动度(n=14,P=0.004)相关,与MMT-8呈负相关(r=-0.59,P=0.02)。
核心结论
- 抗FHL1自身抗体存在于27%的IIM患者中,其中25%其他自身抗体阴性;其他自身免疫病频率和水平较低;抗FHL1水平常随免疫抑制治疗下降,与诊断时疾病活动度指标相关,治疗后很少新出现。
研究设计与样本
- 研究纳入IIM患者449例、自身免疫病对照130例、神经肌肉疾病16例和健康对照100例,采用酶联免疫吸附试验(ELISA)检测诊断时血清抗FHL1自身抗体,并对FHL1阳性和阴性IIM患者进行纵向分析。
主要发现
- 抗FHL1在IIM中阳性122/449(27%),高于自身免疫病和神经肌肉疾病对照13/146(9%,P<0.001)及健康对照3/100(3%,P<0.001)。
- IIM组抗FHL1水平中位数(IQR)为0.62(0.15-1.04),高于自身免疫病对照0.22(0.08-0.58)、健康对照0.35(0.23-0.47)和神经肌肉疾病0.48(0.36-0.80),P<0.001。
- 抗FHL1阳性IIM患者诊断年龄较阴性组更年轻(P=0.05),25%其他自身抗体阴性。
- 首次随访时,基线阳性的33例中20例(60%)抗FHL1转阴;启动治疗后抗FHL1自身抗体很少出现。
- 基线抗FHL1水平与CK(r=0.62,P=0.01)、MYOACT疾病活动度(n=14,P=0.004)相关,与MMT-8呈负相关(r=-0.59,P=0.02)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine prevalence and clinical associations of anti-Four-and-a-half-LIM-domain 1 (FHL1) autoantibodies in patients with idiopathic inflammatory myopathies (IIM) and to evaluate autoantibody levels over time. METHODS: Sera at the time of diagnosis from patients with IIM (n = 449), autoimmune disease controls (DC, n = 130), neuromuscular diseases (NMDs, n = 16) and healthy controls (HC, n = 100) were analysed for anti-FHL1 autoantibodies by enzyme-linked immunosorbent assay (ELISA). Patients with IIM FHL1+ and FHL1- were included in a longitudinal analysis. Serum levels were correlated to disease activity. RESULTS: Autoantibodies to FHL1 were more frequent in patients with IIM (122/449, 27%) compared with DC (autoimmune DC and NMD, 13/146, 9%, P < 0.001) and HC (3/100.3%, P < 0.001). Anti-FHL1 levels were higher in IIM [median (IQR)=0.62 (0.15-1.04)] in comparison with DC [0.22 (0.08-0.58)], HC [0.35 (0.23-0.47)] and NMD [0.48 (0.36-0.80)] P < 0.001. Anti-FHL1+ patients with IIM were younger at the time of diagnosis compared with the anti-FHL1- group (P = 0.05) and were seronegative for other autoantibodies in 25%.In the first follow-up, anti-FHL1+ sample 20/33 (60%) positive at baseline had turned negative for anti-FHL1 autoantibodies. Anti-FHL1 autoantibodies rarely appeared after initiating treatment. Anti-FHL1 autoantibody levels correlated with CK (r = 0.62, P= 0.01), disease activity measured using the Myositis Disease Activity Assessment Tool (MYOACT) (n = 14, P = 0.004) and inversely with Manual Muscle Test-8 (r = -0.59, P = 0.02) at baseline. CONCLUSION: Anti-FHL1 autoantibodies were present in 27% of patients with IIM; of these, 25% were negative for other autoantibodies. Other autoimmune diseases had lower frequencies and levels. Anti-FHL1 levels often decreased with immunosuppressive treatment, correlated with disease activity measures at diagnosis and rarely appeared after start of treatment.
引用
- Galindo-Feria AS, Lodin K, Horuluoglu B, et al. Anti-FHL1 autoantibodies in adult patients with myositis: a longitudinal follow-up analysis. Rheumatology (Oxford). 2025. PMID: 38833674. doi:10.1093/rheumatology/keae317
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。